通化東寶(600867.SH):精蛋白人胰島素注射液獲得境外藥品註冊證書
格隆匯5月13日丨通化東寶(600867.SH)公佈,近日收到尼加拉瓜國家衛生監管局(ANRS)覈準簽發的精蛋白人胰島素注射液的藥品註冊證書(註冊號:06000650325)。公司精蛋白人胰島素混合注射液,適用於1型或2型糖尿病。主要成份爲人胰島素,通過基因重組技術生產,它能促進肝臟、肌肉和脂肪等組織攝取和利用葡萄糖,抑制肝糖原分解及糖異生作用,從而降低血糖水平。精蛋白可使胰島素緩慢釋放,延長其作用時間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.